Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Hangzhou 310003, China.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024 Aug 25;53(4):519-526. doi: 10.3724/zdxbyxb-2024-0002.
To explore the efficacy and safety of tetrandrine in the treatment of rheumatoid arthritis.
Randomized controlled studies of tetrandrine in the treatment of rheumatoid arthritis were searched in CNKI, VIP, Wanfang database, SinoMed, PubMed, Springer, Web of Science and Cochrane Central Register of Controlled Trails databases. A meta-analysis was conducted using R 3.5.3 software to evaluate the clinical outcomes, including the total effective rate, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), visual analogue scale (VAS), disease activity score (DAS), tender joint count (TJC), swollen joint count (SJC), and morning stiffness duration, as well as adverse events of rheumatoid arthritis patients.
A total of 10 articles were included in the study. The meta-analysis indicated that tetrandrine significantly improved the total effective rate (=3.27, 95%: 2.01-5.37, <0.01), ESR (=1.12, 95%: 0.06-2.19, <0.05), CRP (=0.75, 95%: 0.28-1.22, <0.01), VAS (=0.64, 95%: 0.29-1.00, <0.01), TJC (=1.16, 95%: 0.58-1.74, <0.01), SJC (=0.85, 95%: 0.40-1.31, <0.01), and morning stiffness (=1.09, 95%: 0.68-1.50, <0.01). However, no statistical significance was found in RF (=1.70, 95%: －1.10-4.51, >0.05) and DAS (=0.26, 95%: －0.59-1.11, >0.05). The overall incidence of adverse events associated with tetrandrine treatment for rheumatoid arthritis was 20% (95%: 12%-27%, =60%, <0.05), with mild severity and favorable outcomes.
Tetrandrine is effective in the treatment of RA patients with a mild degree of adverse events.
探讨汉防己甲素治疗类风湿关节炎的疗效和安全性。
在 CNKI、VIP、万方数据库、SinoMed、PubMed、Springer、Web of Science 和 Cochrane 中心对照试验注册库中检索汉防己甲素治疗类风湿关节炎的随机对照研究。使用 R 3.5.3 软件进行荟萃分析，评估临床结局，包括总有效率、红细胞沉降率（ESR）、C 反应蛋白（CRP）、类风湿因子（RF）、视觉模拟评分（VAS）、疾病活动评分（DAS）、压痛关节数（TJC）、肿胀关节数（SJC）和晨僵时间，以及类风湿关节炎患者的不良反应。
共纳入 10 项研究。荟萃分析结果显示，汉防己甲素可显著提高总有效率（OR=3.27，95%CI：2.01-5.37，<0.01）、ESR（MD=1.12，95%CI：0.06-2.19，<0.05）、CRP（MD=0.75，95%CI：0.28-1.22，<0.01）、VAS（MD=0.64，95%CI：0.29-1.00，<0.01）、TJC（MD=1.16，95%CI：0.58-1.74，<0.01）、SJC（MD=0.85，95%CI：0.40-1.31，<0.01）和晨僵时间（MD=1.09，95%CI：0.68-1.50，<0.01）。然而，RF（MD=1.70，95%CI：-1.10-4.51，>0.05）和 DAS（MD=0.26，95%CI：-0.59-1.11，>0.05）无统计学意义。汉防己甲素治疗类风湿关节炎的不良反应总发生率为 20%（95%CI：12%-27%，OR=60%，<0.05），不良反应程度较轻，预后良好。
汉防己甲素治疗类风湿关节炎有效，不良反应程度较轻。
